Vous avez cherché: complete blood count (Anglais - Maltais)

blood count
eżami tad-demm

blood count.
baxx.

complete blood count with differential blood count and platelets.
għadd sħiħ tad-demm b’għadd differenzjali tad-demm u plejtlits.

prior to chemotherapy, patients should have a complete blood count.
qabel il-kimoterapija, il-pazjenti għandu jsirilhom għadd sħiħ tad-demm.

during treatment a complete blood count should be obtained weekly.
waqt il-kura, l-għadd komplet tad-demm għandu jinkiseb kull ġimgħa.

if itp is suspected a complete blood count should be obtained immediately.
jekk ikun hemm suspett ta' itp, għandu jinkiseb għadd sħiħ tad-demm immedjatament.

complete blood cell count including differential white blood cell and platelet count.
għadd sħiħ taċ-ċelluli tad-demm li jinkludi għadd ta' ċelluli tad-demm bojod u plejtlits bid- differenzjal.

it is recommended that a complete blood count and platelet count is performed regularly.
hu rrakkomandat li għadd sħiħ tad-demm u għadd tal-plejtlets jitwettqu regolarment.

blood counts
għadd taċ-ċelluli tad-demm

evaluations of your heart function and the condition of your arteries and veins a complete blood count
evalwazzjonijiet tal-funzjoni tal-qalb tiegħek u tal-kondizzjoni tal-arterji u tal-vini tiegħek test biex jara l-għadd sħiħ tad-demm

monitoring of complete blood count is recommended prior to initiating temsirolimus therapy and periodically thereafter.
huwa rrakkomandat monitoraġġ tal-għadd tad-demm sħiħ qabel ma tinbeda t-terapija b’temsirolimus u perjodikament minn hemm ’il quddiem.

complete blood count with differential (prior to treatment initiation and at monthly intervals thereafter)
għadd sħiħ tad-demm bid-differenzjal (qabel il-bidu tal-kura u f'intervalli ta’ kull xahar minn hemm ’il quddiem)

complete blood count results (see above under itp) should be used to monitor for cytopenias.
riżultati ta' għadd sħiħ tad-demm (ara hawn fuq taħt itp) għandhom jintużaw biex jimmonitorjaw għal ċitopeniji.

complete blood cell counts should be performed as clinically indicated.
għandhom isiru diversi għadd komplet taċ-ċelloli tad-demm skont kif ikun klinikament indikat.

prior to initiating treatment with tecfidera, a current complete blood count, including lymphocytes, must be performed.
qabel ma tinbeda l-kura b’tecfidera, għadd sħiħ kurrenti tad-demm, li jinkludi l-limfoċiti, irid jitwettaq.

complete blood counts must be performed regularly during therapy with glivec.
waqt il-kura b’glivec, għandhom isiru testijiet ta’ l-għadd taċ-ċelluli kollha tad-demm, b’mod regolari.

during treatment a complete blood count should be obtained on day 22 (21 days after the first dose of tmz).
waqt il-kura, l-għadd komplet tad-demm għandu jinkiseb f’jum 22 (21 jum wara l-ewwel doża ta’ tmz).

prior to each paclitaxel infusion, patients should have a complete blood count and blood chemistry performed to evaluate hepatic function.
qabel kull infużjoni ta’ paclitaxel, il-pazjenti għandu jsirilhom l-għadd komplet taċ-ċelluli tad-demm u test tal-kimika tad-demm biex tiġi evalwata l-funzjoni epatika.

laboratory tests complete blood counts must be performed regularly during therapy with glivec.
testijiet tal- laboratorju waqt il- kura b’ glivec, għandhom isiru testijiet ta ’ l- għadd taċ- ċelluli kollha tad- demm, b’ mod regolari.

frequent monitoring of complete blood counts should be conducted on all patients receiving docetaxel.
moniteraġġ frekwenti permezz ta’ l-għadd sħiħ taċ-ċelluli tad-demm hu xieraq li ssir fil- pazjenti kollha li qegħdin jirċievu docetaxel.